摘要
肺癌是我国发病率和病死率最高的恶性肿瘤,分子靶向治疗是晚期非小细胞肺癌新的有前景的治疗方法。本文通过介绍以表皮生长因子受体酪氨酸激酶抑制剂为代表的非小细胞肺癌的分子靶向治疗历程,说明了循证医学和个体化治疗在临床肿瘤治疗中的相辅相成,只有将循证医学和个体化治疗结合起来才能不断地提高临床肿瘤治疗水平。
Lung cancer is the leading malignancy of morbidity and mortality in China. Molecular target drugs have greatly influenced the treatment of non small lung cancer（NSCLC）. This article introduced the pathway of EGFR-TKI in treatment of NSCLC, which suggesting the coordination of evidence based medicine and personalized treatment. Only the combination of evidence based medicine and personalized treatment could endlessly improve the clinical treatment of malignancies.
出处
《医学与哲学（B）》
2010年第4期5-6,24,共3页
Medicine & Philosophy(B)
